Arca
Skip to content
Tools
Tools

Liver disease

Drug research and approvals for liver disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,702 studies of liver disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 1 approved and 7 open orphan designations naming it, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 1,702
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 1
  • EU medicines: 8

Recruiting now

Newest posted first, of 1,702 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 12

Phase 2 12 of 21

Phase 1 or earlier 12 of 219

How its trials ended

2,245 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 381 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.

  • Completed, result not reported92141%
  • Ongoing57526%
  • Status unknown36816%
  • Met its primary endpoint1708%
  • Stopped: other or unclear974%
  • Stopped: enrollment or feasibility442%
  • Missed its primary endpoint311%
  • Stopped: sponsor or business decision151%
  • Stopped: lack of efficacy11<1%
  • Stopped: funding11<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 26; search them all in Canada trials
Jul 14, 2026A dose-finding, double-blind, randomized, placebo-controlled phase 2 study to evaluate the efficacy and safety of treatment with efimosfermin alfa in adult…Efimosfermin alfa (GSK6519754)GSKOngoing
May 7, 2026A phase 1/2, open-label, multi-center, dose escalation, dose expansion, and single repeat dose study of TSRA-196 in adults with the pizz genotype who have lung…TSRA-196Tessera Therapeutics, Inc.Pending
Nov 6, 2025A master protocol for a randomized, controlled, clinical trial of multiple pharmacologic agents in adult participants with metabolic dysfunction-associated…Retatrutide (LY3437943) / Tirzepatide (LY3298176)Eli LillyOngoing
Mar 28, 2025Stimulating adipose tissue fatty acid disposal with low-dose, postprandial, intermittent niacin for the treatment of metabolic dysfunction-associated steatotic…Nicotinic acid / Albumin / 11C palmitate / 18F fthaCiusss De L'Estrie - Centre Hospitalier Universitaire De SherbrookePending
Mar 7, 2025A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of denifanstat in patients with metabolic dysfunction…Denifanstat (TVB-2640)Sagimet BiosciencesClosed
Oct 29, 2024A dose-finding, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of GSK4532990 for steatohepatitis in adults with alcohol…GSK4532990GSKOngoing
May 31, 2024A phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of NST-6179 in adult…Orziloben (NST-6179)Northsea Therapeutics B.V.Closed
Feb 14, 2024Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver…NNC0194-0499 / Cagrilintide-semaglutide/ Cagrilintide/ SemaglutideNovo NordiskOngoing
Jan 23, 2024A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of fazirsiran in the treatment of ALPHA-1 antitrypsin…Fazirsiran (TAK-999)Takeda Pharmaceuticals USAOngoing
Sep 12, 2023A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed…Efruxifermin (EFX)Akero TherapeuticsOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jul 27, 2018OmegavenOmegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)Fresenius Kabi USA, LLCApproved
Feb 12, 2026Fully synthetic medium-chain fatty acid analogueTreatment of intestinal failure associated liver diseaseNorthSea Therapeutics B.V.Designated
Sep 15, 2021OctreotideTreatment of autosomal dominant polycystic liver diseaseCamurus ABDesignated
Mar 28, 2018FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)Sterotherapeutics, LLCDesignated
May 14, 2014Menadione sodium bisulfiteTreatment of autosomal dominant polycystic liver diseaseIC-MedTech CorporationDesignated
Nov 20, 2013EmricasanTreatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver diseaseConatus Pharmaceuticals Inc.Designated
Apr 15, 2013Sodium ascorbate and menadione sodium bisulfiteTreatment of autosomal dominant polycystic liver diseaseIC-Medtech CorporationDesignated
Oct 23, 2007UrsodiolTreatment of cystic fibrosis liver diseaseAsklepion Pharmaceuticals, LLCDesignated

Medicines authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.